echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Reduce the risk of disease progression by 37% Janssen CD38 antibody combination approved for second-line treatment of MM

    Reduce the risk of disease progression by 37% Janssen CD38 antibody combination approved for second-line treatment of MM

    • Last Update: 2021-08-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Janssen, a subsidiary of Johnson & Johnson, today announced that the U.


    This approval is based on the results of a phase 3 clinical trial called APOLLO


    In addition, the results of the study showed that Darzalex Faspro+Pd had a higher overall remission rate (69% vs.


    Darzalex Faspro, jointly developed by Janssen and Genmab, is the first anti-CD38 antibody that can be administered by subcutaneous injection, reducing the time for patients to receive treatment from a few hours to a few minutes


    Note: The original text has been deleted

    Reference materials:

    [1] Janssen Announces US FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.